Manuel Palacios
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manuel Palacios has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Martínez-López
Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Murcia, Spain
1 shared publication Andrés Jérez
Departamento de Hematología y Oncología Clínica, Hospital General Universitario Morales Meseguer, Murcia, Spain
1 shared publicationCristina Beléndez
Centro de Investigación Biomédica en Red (CIBERER), ISCIII, Madrid, Spain
1 shared publication- Cristina Díaz de Heredia
Department of Pediatric Hematology and Oncology, Hospital Universitari Vall d’Hebron, Barcelona, Spain
1 shared publication - Diana García-Moreno
Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Spain
1 shared publication Francisca Ferrer-Marín
Centro de Investigación Biomédica en Red (CIBERER), ISCIII, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 9 January 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (2) , 702-724
TKI-mediated inhibition of NLRP1 inflammasome restores erythropoiesis in DBA syndrome
Diamond-Blackfan anemia syndrome (DBAS) is marked by defective erythropoiesis caused by impaired ribosome biogenesis and aberrant signaling. Here, we investigate how ribosomal stress-induced activation of the NLRP1 inflammasome affects erythroid differentiation in DBAS. We demonstrate that FDA/EMA-approved tyrosine kinase inhibitors (TKIs) effectively mitigate defective erythropoiesis by inhibiting NLRP1 inflammasome activation. In K562 cells, nilotinib suppresses the ZAKα/P38/NLRP1/CASP1 axis, leading to increased GATA1 levels and upregulation of key erythroid genes. These effects were validated in human CD34⁺ hematopoietic stem and progenitor cells (HSPCs) and zebrafish models, where nilotinib, imatinib, and dasatinib promoted erythropoiesis while reducing caspase-1 activity. In Rps19-deficient zebrafish, RPS19-deficient human HSPCs, and HSPCs from DBAS patients, TKIs rescued erythroid differentiation and restored hemoglobin levels. Our findings highlight that targeting the NLRP1 inflammasome with TKIs may provide a novel therapeutic strategy for DBAS and other ribosomopathies.
- 9 January 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (2) , 702-724
Open AccessTKI-mediated inhibition of NLRP1 inflammasome restores erythropoiesis in DBA syndrome
Diamond-Blackfan anemia syndrome (DBAS) is marked by defective erythropoiesis caused by impaired ribosome biogenesis and aberrant signaling. Here, we investigate how ribosomal stress-induced activation of the NLRP1 inflammasome affects erythroid differentiation in DBAS. We demonstrate that FDA/EMA-approved tyrosine kinase inhibitors (TKIs) effectively mitigate defective erythropoiesis by inhibiting NLRP1 inflammasome activation. In K562 cells, nilotinib suppresses the ZAKα/P38/NLRP1/CASP1 axis, leading to increased GATA1 levels and upregulation of key erythroid genes. These effects were validated in human CD34⁺ hematopoietic stem and progenitor cells (HSPCs) and zebrafish models, where nilotinib, imatinib, and dasatinib promoted erythropoiesis while reducing caspase-1 activity. In Rps19-deficient zebrafish, RPS19-deficient human HSPCs, and HSPCs from DBAS patients, TKIs rescued erythroid differentiation and restored hemoglobin levels. Our findings highlight that targeting the NLRP1 inflammasome with TKIs may provide a novel therapeutic strategy for DBAS and other ribosomopathies.